https://doi.org/10.55788/2cdaf94c
In this podcast (09:36) we’re diving into highlights from the European Association of Dermatology and Venereology, or EADV, Annual Meeting held in Amsterdam, the Netherlands from 25 to 28 September 2024. In this episode, we’ll cover 6 key sessions that focus on advances in dermatology. You could say we've got skin in the game when it comes to bringing you the latest dermatology research!
- Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
- IL-13 inhibitor shows safety and efficacy in AD over 3 years
- Deuruxolitinib significantly improves hair satisfaction in alopecia areata
- Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
- soBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
- Prurigo nodularis: long-term treatment reduces relapse events
Posted on
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com